SESSION 5 | 15:55 – 16:35
VEGF related and other retinal indications
Moderators: Anat Loewenstein / Francesco Bandello
15:55
Sergio Leal, Bayer — Bayer’s vision for the future of ophthalmology
16:00
George Magrath, Ocuphire Pharma — The Evolution of Ocuphire: Leading the Way in Diabetic Retinopathy
16:05
Riad Sherif, Oculis — OCS-01, an OPTIREACH® formulation of high concentration dexamethasone eye drop, for the treatment of DME
16:10
Frederic Guerard, Opthea — Sozinibercept in wet AMD: Potential for superior vision outcomes beyond anti-VEGF-A therapies
16:15
Robert Kim, 4D Molecular Therapeutics — 4D Molecular Therapeutics: New Era of Genetic Medicine
16:20
Sumie Takahara, Regenxbio — Innovation to address unmet needs in retinal diseases
16:25
Panel Discussion — Anat Loewenstein, Francesco Bandello, Sergio Leal,
George Magrath, Riad Sherif, Frederic Guerard, Robert Kim & Sumie Takahara